Sign In
Buy KROS
$10.50
-0.0500 (-0.474%)
At Close: Jun 03, 2026
Keros Therapeutics Announces Participation at Goldman Sachs 47th Annual Global Healthcare Conference
04:01pm, Monday, 01'st Jun 2026
LEXINGTON, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel th
Should You Buy KROS After Q1 Miss and Takeda Deal Reset?
12:11pm, Friday, 22'nd May 2026
Keros faces a volatile setup after its Q1 miss, with a longer cash runway and leaner costs balanced against uncertain milestone-driven revenue.
KROS Turns to Next Wave of TGF-Beta Muscle Therapies
12:11pm, Friday, 22'nd May 2026
Keros is shifting toward rinvatercept-led neuromuscular development, with phase II plans, early human signals and cash runway shaping the KROS story.
KROS Stock Guide to Rinvatercept in DMD and ALS for 2026
12:06pm, Friday, 22'nd May 2026
Keros heads into 2026 with rinvatercept catalysts in DMD and ALS as investors watch phase II plans, orphan status and early clinical signals.
Keros Q1 Loss Wider Than Expected, Revenues Plunge Year Over Year
01:11pm, Friday, 15'th May 2026
KROS posts a wider Q1 loss as revenues fall due to the absence of license revenues. The company advances rinvatercept and elritercept studies.
Keros Therapeutics, Inc. (KROS) Reports Q1 Loss, Misses Revenue Estimates
10:10am, Thursday, 14'th May 2026
Keros Therapeutics, Inc. (KROS) came out with a quarterly loss of $1.21 per share versus the Zacks Consensus Estimate of a loss of $0.92. This compares to earnings of $3.62 per share a year ago.
Keros Therapeutics Reports Recent First Quarter 2026 Financial Results
08:00am, Thursday, 14'th May 2026
LEXINGTON, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and comm
KROS 2026 Watchlist: 3 Catalysts That Could Reset Sentiment
12:46pm, Monday, 20'th Apr 2026
Keros heads into 2026 with three key catalysts, including DMD study start, ALS regulatory talks, and Takeda progress, that could reshape investor sentiment.
KROS Stock: Does the Takeda Deal Lower Dilution Risk in 2026?
12:41pm, Monday, 20'th Apr 2026
Keros Therapeutics KROS reshaped its financial profile in 2025 by pairing a major licensing transaction with a shift in development responsibilities. The result was a step-change in reported revenue
KROS Rinvatercept: What to Know Before DMD Phase II Starts
12:30pm, Monday, 20'th Apr 2026
KROS sharpens focus on rinvatercept as a phase II DMD study looms in 2026, shifting the story toward execution and high-stakes clinical catalysts.
JPMorgan Chase & Co. Raises Position in Keros Therapeutics, Inc. $KROS
04:45am, Monday, 06'th Apr 2026
JPMorgan Chase and Co. grew its position in shares of Keros Therapeutics, Inc. (NASDAQ: KROS) by 260.8% during the third quarter, according to the company in its most recent disclosure with the Securi
Why Is Keros Therapeutics (KROS) Up 2.5% Since Last Earnings Report?
12:31pm, Friday, 03'rd Apr 2026
Keros Therapeutics (KROS) reported earnings 30 days ago. What's next for the stock?
KROS Stock: What to Know About Rinvatercept in DMD
02:20pm, Tuesday, 17'th Mar 2026
Keros advances rinvatercept in DMD with orphan status, fresh phase I data, and a planned Q2 2026 phase II start driving its near-term execution story.
KROS: Is the Discount Book Value a Value Trap?
02:20pm, Tuesday, 17'th Mar 2026
Keros posts a 2025 revenue surge from Takeda licensing, but no product sales and volatile drivers leave investors weighing a discounted valuation against execution risk.
KROS Pipeline Catalysts: DMD Phase II and ALS Plans for 2026
02:20pm, Tuesday, 17'th Mar 2026
Keros lines up 2026 catalysts with rinvatercept at the core, including a Q2 DMD phase II start and ALS regulatory plans as execution shifts into focus.
